Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

Exclusion Criteria

• •Pregnant females or females who plan to become pregnant during the study
• •Drug or alcohol abuse within the past 3 years
• •Use of any investigational drug with 30 days of the start of the study
• •Eczema or other skin conditions associated with itching (besides hives)
• •Inability to comply with follow-up procedures
• •Use of the following therapies in the past 30 days: hydroxychloroquine, sulfasalazine, dapsone, methotrexate, cyclophosphamide, Intravenous Immunoglobulin (IVIG), plasmapheresis, cyclosporine, oral or systemic steroids, or other monoclonal antibody therapies
• •Use of doxepin within the past 2 weeks
• •Use of either H2 antihistamines and leukotriene receptor antagonists within 7 days before starting the study (unless already on these medications for Gastroesophageal Reflux Disease (GERD), asthma or allergic rhinitis)
• •Inability to take diphenhydramine (Benadryl)
• •Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks or interfere with ability to comply with study procedures.